Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 710-716

  Chow, Justin ^a   Liu, Yanzhou ^a   Comstock, Kate ^a   Brandl, Michael ^a   Lin, Fangling ^a   Li, Fujun ^a   Sarma, Keshab ^a   Alfredson, Tom ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Heart cut and recycle chromatography; Hepatitis C; Preparative chromatography; Related impurities; RG7128

Indexed keywords

ESTER DERIVATIVE; MW 259; MW 329; MW 371; MW 385; MW 399; MW 469; PRODRUG; RG 7128; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHROMATOGRAPHY; DRUG IDENTIFICATION; DRUG IMPURITY; DRUG ISOLATION; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HEART CUT AND RECYCLE CHROMATOGRAPHY; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOMER; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DRUG CONTAMINATION; ESTERS; HEPATITIS C; MAGNETIC RESONANCE SPECTROSCOPY; RNA REPLICASE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 77954862179     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.04.003     Document Type: Article

References (12)

1. Gane E., Roberts S., Stedman C., Angus P., Ritchie B., et al. 60th Annual Meeting of the American Association for the Study of Liver Diseases October 30-November 3, 2009.
2. Le Pogam S., Kang H., Seshaadri A., Kosaka A., Hu S., et al. 44th Annual Meeting of the European Association for the Study of the Liver April 22-26, 2009.
3. Lalezari J., Gane E., Rodriguez-Torres M., DeJesus E., Nelson D., et al. 43rd Annual Meeting of European Association for the Study of the Liver April 23-27, 2008.
4. McHutchison J., Reddy R., Rodriguez-Torres M., Gane E., Robson R., et al. Frontiers in Drug Development in Viral Hepatitis December 9-13, 2007.
5. Reddy R., Rodriguez-Torres M., Gane E., Robson R., Lalezari J., et al. 58th Annual Meeting of the American Association for the Study of Liver Diseases (Poster LB9) November 2-6, 2007.
6. International Conferences on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH harmonized Tripartite Guideline, Impurities in New Drug Substances. Q3A(R2). October 25 2006.
7. Reddy K.K., Rao S.M., Reddy G.O., Babu T.S.J.M., Dubey P.K., Vyas K. Isolation and characterization of process-related impurities in linezolid. J. Pharm. Biomed. Anal. 2003, 30:635-642.
8. Reddy K.K., Babu J.M., Dubey P.K., Sekhar B.C., Reddy G.O., Vyas K. Isolation and characterization of process-related impurities in rofecoxib. J. Pharm. Biomed. Anal. 2002, 29:355-360.
9. Sigvardson K.W., Adams S.P., Barnes T.B., Blom K.F., Fortunak J.M., Haas M.J., Reilly K.L., Repta A.J., Nemeth G.A. The isolation and identification of a toxic impurity in XP315 drug substance. J. Pharm. Biomed. Anal. 2002, 27:327-334.
10. Gorog S. Chemical and analytical characterization of related organic impurities in drugs. Anal. Bioanal. Chem. 2003, 377:852-862.
11. Pan C., Liu F., Ji Q., Wang W., Drinkwater D., Vivilecchia R. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development. J. Pharm. Biomed. Anal. 2006, 40:581-590.
12. Niessen W.M.A., Lin J., Bondoux G.C. Developing strategies for isolation of minor impurities with mass spectrometry-directed fractionation. J. Chromatogr. A 2002, 970:131-140.